Chronic pain, a global health burden exacerbated by the limitations and risks of current opioid-based therapies, necessitates the discovery of novel, non-addictive analgesics. Animal venoms represent rich, evolutionarily refined libraries of ion channel modulators with high potential for drug development. The venom of the medically significant scorpion Parabuthus transvaalicus is a potent neurotoxic cocktail, primarily causing excruciating pain, yet paradoxically it may harbour compounds capable of silencing nociception. This study provides a comprehensive pharmacological evaluation of P. transvaalicus venom to isolate and characterize neurotoxic components for their analgesic potential.

Sequential chromatographic fractionation of the crude venom yielded 32 discrete fractions, from which eight principal neurotoxins (Pt2, Pt5, Pt8, Pt11, Pt15, Pt22, Pt25, and Pt28) were purified and characterized. Automated and manual patch-clamp electrophysiology on recombinant human ion channels revealed starkly divergent pharmacological profiles. While known toxins like the β-Na_V toxin Pt2 acted as a broad-spectrum sodium channel activator (shifting V_1/2 of activation by -15 to -25 mV), the novel long-chain toxin Pt25 emerged as a potent and selective inhibitor of the key pain-related isoforms Na_V1.7 (IC₅₀ = 8.7 ± 1.2 nM) and Na_V1.8, displaying >50-fold selectivity over cardiac Na_V1.5. Furthermore, the novel short-chain toxin Pt22 was identified as a positive allosteric modulator of K_V7.2/7.3 channels (M-current), causing a -18.5-mV shift in the voltage dependence of activation (EC₅₀ = 88 nM), a novel mechanism for a scorpion venom peptide.

In vivo behavioural assays in murine models confirmed this functional duality. Local injection of Pt2 induced immediate pain and hyperalgesia, whereas systemic administration of Pt25 (1 µg/kg, s.c.) or Pt22 (10 µg/kg, s.c.) produced significant analgesia in both acute nociceptive and chronic constriction injury (CCI) neuropathic pain models, without impairing motor function. Notably, sub-effective doses of Pt25 and Pt22 demonstrated synergistic analgesic interaction. Rational in silico design and mutagenesis yielded an optimized analogue of Pt25 (Pt25-M1) with enhanced selectivity and an improved therapeutic index.